Search

Your search keyword '"VISCERAL leishmaniasis"' showing total 2 results
Start Over Descriptor "VISCERAL leishmaniasis" Topic cutaneous leishmaniasis Topic l. infantum
2 results on '"VISCERAL leishmaniasis"'

1. First molecular detection and identification of Leishmania species in small wild rodents from Turkey.

Author

Karakuş, Mehmet, Öktem, Mehmet Ali, Sözen, Mustafa, Matur, Ferhat, Çolak, Faruk, Nalçaci, Muhammed, Özbel, Yusuf, and Töz, Seray

Subjects
*VETERINARY parasitology, *LEISHMANIA, *CUTANEOUS leishmaniasis, *RODENTS, *VISCERAL leishmaniasis
Abstract

Leishmaniasis is a parasitic disease infecting animals and humans. Two clinical forms (Visceral and cutaneous leishmaniasis) and four species are reported to be present in Turkey. Several studies have investigated canine and human leishmaniasis in Turkey but no study was performed to screen the infection among wild rodents, so far. The present study aims to investigate the role of small wild rodents as reservoir animals for Leishmania spp. in different regions of Turkey. Formalin-preserved tissue samples (spleen, liver, lung) of 712 rodents from 30 provinces were screened for the presence of Leishmania spp. DNA. Before DNA extraction, tissues were dried, rehydrated, and homogenated. Leishmania screening in rodent tissues and species determination was performed with a combination of real-time kDNA and ITS1 polymerase chain reaction protocols. Eight (1.12%) out of 712 animals were found to be positive for Leishmania spp. DNA and species typing revealed five L. infantum, two L. tropica and one L. major among positives. Leishmania major and L. infantum DNA were detected in Apodemus spp. from Zonguldak province located in the Western Black Sea Region, while L. tropica DNA was found in Meriones sp. and Gerbillus dasyurus from Adana and Hatay provinces located in Eastern Mediterranean Region of Turkey. The present study is first to report natural infection of L. infantum, L. major and L. tropica in small wild rodents in Turkey, suggesting their possible roles as reservoirs. Further studies are needed for planning epidemiological studies and also for developing rodent control measures in risky endemic areas to break the transmission cycle. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

2. Design, synthesis, in vitro – In vivo biological evaluation of novel thiazolopyrimidine compounds as antileishmanial agent with PTR1 inhibition.

Author

Istanbullu, Huseyin, Bayraktar, Gulsah, Karakaya, Gulsah, Akbaba, Hasan, Perk, Nami Ege, Cavus, Ibrahim, Podlipnik, Crtomir, Yereli, Kor, Ozbilgin, Ahmet, Debelec Butuner, Bilge, and Alptuzun, Vildan

Subjects
*VECTOR-borne diseases, *PROTOZOAN diseases, *LEISHMANIASIS, *MOLECULAR docking, *VISCERAL leishmaniasis
Abstract

The leishmaniasis are a group of vector-borne diseases caused by a protozoan parasite from the genus Leishmania. In this study, a series of thiazolopyrimidine derivatives were designed and synthesized as novel antileishmanial agents with Lm PTR1 inhibitory activity. The final compounds were evaluated for their in vitro antipromastigote activity, Lm PTR1 and h DHFR enzyme inhibitory activities, and cytotoxicity on RAW264.7 and L929 cell lines. Based on the bioactivity results, three compounds, namely L24f , L24h and L25c , were selected for evaluation of their in vivo efficacy on CL and VL models in BALB/c mice. Among them, two promising compounds, L24h and L25c, showed in vitr o antipromastigote activity against L. tropica with the IC 50 values of 0.04 μg/ml and 6.68 μg/ml; against L. infantum with the IC 50 values of 0.042 μg/ml and 6.77 μg/ml, respectively. Moreover, the title compounds were found to have low in vitro cytotoxicity on L929 and RAW264.7 cell lines with the IC 50 14.08 μg/ml and 21.03 μg/ml, and IC 50 15.02 μg/ml and 8.75 μg/ml, respectively. Lm PTR1 enzyme inhibitory activity of these compounds was determined as 257.40 μg/ml and 59.12 μg/ml and their selectivity index (SI) over h DHFR was reported as 42.62 and 7.02, respectively. In vivo studies presented that L24h and L25c have a significant antileishmanial activity against footpad lesion development of CL and at weight measurement of VL group in comparison to the reference compound, Glucantime®. Also, docking studies were carried out with selected compounds and other potential Leishmania targets to detect the putative targets of the title compounds. Taken together, all these findings provide an important novel lead structure for the antileishmanial drug development. [Display omitted] • A series of thiazolopyrimidine derivatives were synthesized as novel antileishmanials. • L24f , L24h and L25c showed in vitro antipromastigote activity and low cytotoxicity. • L24f , L24h and L25c showed moderate Lm PTR1 inhibition and h DHFR selectivity. • L24h and L25c have shown in vivo activity on CL and VL models of BALB/c mice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results